标签： Antigua and Barbuda

The Caribbean Community (CARICOM) has formally expressed apprehension regarding recent immigration measures enacted by the United States government. On December 16, 2025, the US issued a proclamation imposing partial entry restrictions on nationals from Antigua and Barbuda and the Commonwealth of Dominica, prompting a diplomatic response from the regional body.

While acknowledging the sovereign right of nations to regulate border entry, CARICOM’s Bureau of the Conference of Heads of Government highlighted several significant concerns. The organization emphasized that the decision was implemented without prior consultation, despite the potential for adverse consequences on legitimate travel and people-to-people exchanges. The move is particularly troubling for these small island states, where such restrictions could substantially impact social and economic well-being.

Additionally, CARICOM raised questions regarding the ambiguous status of existing visas beyond January 1, 2026, noting that the lack of clarity creates uncertainty for travelers and diplomatic relations. The regional group has called for immediate engagement between US authorities and the governments of affected nations to clarify the proclamation’s provisions and address outstanding issues.

Reaffirming its commitment to international cooperation, CARICOM emphasized the importance of dialogue founded on mutual respect, shared interests, and adherence to the rule of law. The organization continues to prioritize regional prosperity and the welfare of Caribbean citizens through diplomatic channels, hoping to resolve the matter in accordance with the longstanding partnership between the United States and CARICOM member states.

In a significant diplomatic development, Antigua and Barbuda has secured crucial assurances from the United States regarding visa arrangements following Washington’s recent security proclamation. Ambassador Sir Ronald Sanders, acting under direct instructions from Prime Minister Gaston Browne, held high-level discussions with U.S. State Department officials to address concerns arising from the December 16, 2025 proclamation restricting foreign national entry.

The negotiations yielded three key agreements that provide substantial protection for Antiguan and Barbudan citizens. First, all currently valid U.S. visas held by passport holders will remain fully recognized and accepted for entry without exception. This comprehensive protection covers all visa categories including tourist (B-1/B-2), exchange visitor (J), and student (M) visas.

Second, U.S. authorities confirmed there will be no revocation of any visas issued to nationals prior to December 31, 2025. This guarantee provides stability for existing visa holders amid changing security protocols.

Third, for new visa applications submitted after December 31, 2025, both governments will develop mutually agreeable arrangements focusing specifically on biometric information collection. The enhanced system will ensure full compatibility with U.S. biometric standards while applying equally to all citizens regardless of acquisition method—whether by birth, descent, naturalization, or investment.

Ambassador Sanders expressed appreciation for the constructive engagement from U.S. officials, acknowledging America’s security concerns while emphasizing Antigua and Barbuda’s commitment to cooperative security measures. The agreement represents a balanced approach that protects U.S. national security interests while preserving legitimate travel and people-to-people exchanges between the two nations.

The United Progressive Party (UPP) of Antigua and Barbuda has issued a formal commendation honoring the Republic of Cuba for its decades of substantial contributions to the nation’s development. This praise specifically highlights the pivotal role of Cuban medical diplomacy, which deployed hundreds of healthcare professionals to serve the Antiguan and Barbudan populace.

A cornerstone of this bilateral cooperation was the acclaimed Eye-Care Programme, implemented during the UPP administration of former Prime Minister Baldwin Spencer. This initiative provided critical ophthalmological services, delivering life-changing care to hundreds of citizens and establishing a benchmark for international medical collaboration.

Beyond healthcare, Cuba’s educational assistance program is recognized as a transformative force. The UPP emphasized that hundreds of Antiguan students received university-level training in diverse professional disciplines—opportunities that would have been financially unattainable for most families. This investment in human capital is credited with elevating numerous graduates and their families from poverty, thereby securing a more prosperous socioeconomic future.

The UPP’s statement also reflected on the profound mutual respect and affection shared between Cuban officials and party representatives, characterizing the long-term relationship as genuinely cordial and productive. A note of regret was expressed regarding the current administration’s decision to abruptly terminate this partnership, which the UPP deemed mutually beneficial. Concluding with a pledge of enduring gratitude, the party assured Cuba that its generosity, offered from its own limited resources, would remain etched in the nation’s memory and prayers.

In a landmark move that signals a significant transformation in U.S. drug policy, President Donald Trump enacted an executive order on Thursday directing the potential reclassification of marijuana from its current status as a Schedule I substance to the less restrictive Schedule III category. This administrative action represents the most substantial federal cannabis policy reform in decades and aligns federal approaches more closely with policies already implemented by 40 states and Washington, D.C.

The executive order mandates the Drug Enforcement Administration (DEA) to expedite the rescheduling process, which would relocate cannabis from its current classification alongside heroin and LSD to Schedule III, placing it in the same category as ketamine and certain anabolic steroids. While this change would not establish nationwide recreational legalization, it would fundamentally alter the regulatory landscape for the cannabis industry and substantially reduce the crippling tax burdens that have hampered legitimate marijuana businesses.

President Trump emphasized the medical imperative behind his decision, stating he had received overwhelming public support for the policy shift. ‘We have people begging for me to do this. People that are in great pain,’ the President remarked during the signing ceremony. The order additionally calls for expanded research into and access to CBD products, including a proposed Medicare pilot program that would provide senior citizens with doctor-recommended, hemp-derived CBD at no cost.

Despite growing public support for cannabis reform—with Gallup polling indicating 64% of Americans now favor legalization—the policy change faces significant opposition from within the President’s own party. More than twenty Republican senators, including several staunch Trump allies, signed a letter earlier this year urging the administration to maintain marijuana’s Schedule I status, arguing that rescheduling would undermine public safety and potentially benefit foreign adversaries like China.

The complex rescheduling process, which typically involves extensive scientific review and public comment periods, had already been initiated under the previous administration but encountered substantial resistance within the DEA. Trump’s order directs agencies to complete the procedure as rapidly as legally permissible, though no specific timeline has been established.

Critics from both sides of the debate have emerged. Law enforcement veterans expressed concern about perceived contradictions in simultaneously escalating the war against drugs like fentanyl while relaxing marijuana restrictions. Meanwhile, cannabis advocacy organizations have indicated they may pursue legal action if the rescheduling proceeds, arguing that the government should pursue full decriminalization rather than partial reform.

The Department of Health and Human Services has documented approximately 30,000 licensed healthcare practitioners currently authorized to recommend medical marijuana to over six million patients across at least fifteen medical conditions. The Food and Drug Administration has acknowledged credible scientific support for cannabis in treating anorexia-related conditions, nausea, vomiting, and chronic pain—particularly among older adults, one-third of whom suffer from persistent pain conditions.